[go: up one dir, main page]

US20060078580A1 - Organo-gel formulations for therapeutic applications - Google Patents

Organo-gel formulations for therapeutic applications Download PDF

Info

Publication number
US20060078580A1
US20060078580A1 US11/150,254 US15025405A US2006078580A1 US 20060078580 A1 US20060078580 A1 US 20060078580A1 US 15025405 A US15025405 A US 15025405A US 2006078580 A1 US2006078580 A1 US 2006078580A1
Authority
US
United States
Prior art keywords
composition
agent
ester
urea
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/150,254
Other languages
English (en)
Inventor
Frederick Dechow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MediQuest Therapeutics Inc
Original Assignee
MediQuest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/960,516 external-priority patent/US7740875B2/en
Application filed by MediQuest Therapeutics Inc filed Critical MediQuest Therapeutics Inc
Priority to US11/150,254 priority Critical patent/US20060078580A1/en
Assigned to MEDIQUEST THERAPEUTICS, INC. reassignment MEDIQUEST THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DECHOW, FREDERICK J.
Priority to CA002567575A priority patent/CA2567575C/fr
Priority to PCT/US2005/036064 priority patent/WO2006042059A1/fr
Priority to JP2007535827A priority patent/JP2008515911A/ja
Priority to AU2005294216A priority patent/AU2005294216C1/en
Priority to BRPI0512583A priority patent/BRPI0512583B8/pt
Priority to KR1020077003283A priority patent/KR20070072482A/ko
Priority to NZ551887A priority patent/NZ551887A/en
Priority to SG200906727-3A priority patent/SG156624A1/en
Priority to US11/246,296 priority patent/US7776349B2/en
Priority to CN2005800342224A priority patent/CN101035509B/zh
Priority to EP05811827A priority patent/EP1796632A4/fr
Priority to MX2007003995A priority patent/MX2007003995A/es
Publication of US20060078580A1 publication Critical patent/US20060078580A1/en
Priority to IL180691A priority patent/IL180691A/en
Priority to US12/856,292 priority patent/US20100305081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • This disclosure relates to a composition useful in the local delivery of cosmetic and/or pharmaceutical agents into the skin and nails.
  • This composition allows the formulation with the agent(s) to be rapidly absorbed through the skin, to pass through nails, and also to have a pleasing, non-greasy, non-oily appearance and feel.
  • the skin is the largest organ in the body and serves important functions that are necessary to life.
  • the skin acts as a barrier to the invasion of various pathogens and toxic substances.
  • Skin is composed of the two layers: the epidermis is the first layer; and the dermis is the layer below the epidermis.
  • the skin is highly impermeable. It must be impermeable to preserve its own integrity while at the same time maintaining the delicate dynamic electrolyte balance of the body.
  • the skin must serve a containment function; it must also function as a microbial, chemical, radiation and thermal barrier.
  • the horny cutaneous plates on the dorsal surface of the distal end of the terminal phalanx of a finger or toe (fingernails and toenails). They are made up of flattened epithelial scales developed from specialized epithelial cells called the matrix. The thick and hardened nature of nails renders access through, and to the area below, nearly impossible with current topical formulations.
  • the subject of the present disclosure has the advantage of being able to delivery pharmaceutical agents through the unguis to heretofore minimally accessible disease targets.
  • the art has turned to the use of specifically selected vehicles and carriers into which the pharmaceutical active is incorporated so that the vehicle or carrier aids in, or at a minimum does not adversely affect, the penetration of the selected active agent.
  • the art recognizes that to a vast degree the rate of percutaneous delivery of a pharmaceutical active can be significantly decreased by the selection of an improper vehicle.
  • the advantages of this form of delivery include, but are not limited to: avoidance of the risks associated with parenteral treatment; elimination of the inconveniences of parenteral treatment; avoidance of the variable rates of absorption and metabolism inherent in oral treatment; increasing the continuity of drug administration by permitting delivery of agents with short biological half-lives; and elimination of gastrointestinal irritation resulting from exposing the gastrointestinal tract to pharmaceutical actives, preservatives, tableting agents, and the like.
  • topical delivery possesses the potential for effectively treating conditions which are local in nature (or which exhibit local manifestations), systemically as well as locally with the same treatment regimen.
  • effective compositions to deliver pharmaceutical agents are highly sought after.
  • compositions have been suggested for the precutaneous delivery of certain pharmaceutically active agents, a need exists for achieving enhanced delivery of cosmetic and pharmaceutical agents to the skin for local treatment of skin conditions and diseases.
  • the composition should be easy to apply topically in a quantitative amount, to allow the active agent to rapidly permeate the skin to get where the agent is needed, to have a pleasant odor and appearance, and to not require cleansing to remove the agent.
  • the present disclosure relates to a composition for the local delivery of at least one cosmetic or pharmaceutical agent or both.
  • the composition comprises at least two biocompatible organic solvents, a polar lipid, at least one surfactant, water, urea and a thickener.
  • the organic solvents comprise an ester and a dihydric and/or polyhydric alcohol.
  • the composition comprises about 2 to about 30% by weight of the ester and about 0.5 to about 20% by weight of the dihydric and/or polyhydric alcohol.
  • the present disclosure also relates to a method of delivering an active agent into and through the epidermis or ungual tissue of a human or animal comprising topically applying to the skin or to the nail of the human or animal a composition comprising a cosmetic and/or pharmaceutically active agent and the composition disclosed above.
  • compositions comprising the above disclosed delivery composition and a cosmetic and/or pharmaceutically active agent.
  • the pH of the composition containing the active agent is typically about 5.5 to about 7.5.
  • a still further aspect of the present invention relates to a method for making a composition suitable for the cutaneous delivery of a cosmetic and/or pharmaceutically active agent which comprises:
  • the present disclosure further relates to a composition prepared by the above disclosed method.
  • topical administration is meant directly laying or spreading upon epidermal or ungual tissue, especially outer skin, nails, or membrane, including the skin or membrane of the oral, rectal, or vaginal cavities.
  • safety and effective amount is meant a sufficient amount of the composition to provide the desired local therapeutic activity and performance at a reasonable benefit/risk ratio attendant any medical treatment.
  • amount of active agent used will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the specific active ingredient(s) employed, its or their concentration, the condition of the patient, concurrent therapies being administered, and like factors within the specific knowledge and expertise of the patient or the attending physician.
  • ERTAINly- or pharmacologically-acceptable is meant the pharmaceutical actives, as well as other compatible drugs, medicaments or inert ingredients which the term describes are suitable for use in contact with the tissues of human and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • compositions and methods of this invention are meant that various other compatible cosmetics, drugs and medicaments, as well as inert ingredients, occlusive agents, and cosmetic vehicles, can be conjointly employed in the compositions and methods of this invention, as long as the critical binary penetration enhancement vehicle and cosmetic or pharmaceutical active are used.
  • the term “comprising” thus encompasses and includes the more restrictive terms “consisting of” and “consisting essentially of” which characterize the use of the essential ingredients in the manner disclosed herein.
  • afflicted sites is meant a localized area of pathology, discomfort, infection, inflammation or lesion, and the immediately surrounding area.
  • application sites is meant a site suitable for application via a mechanical sustained release device or dressing, e.g., behind the ear, on the arm, back, top of the foot, etc.
  • penetration-enhancing is meant that the binary penetration enhancing carriers of this disclosure provide marked transepidermal, transungual or percutaneous delivery of an incorporated active, when compared to other compositions at equal chemical potential.
  • This latter aspect is important, since varying solubilities of cosmetics or drugs in different vehicles will necessarily affect their transport across skin or through nails.
  • the lower solubility carrier will show a misleading six-fold difference in transport over the more soluble vehicle.
  • the simplest way of assuring equal chemical potential for evaluating penetration enhancement is to use saturated solutions or solutions of equal percentage of saturation of pharmacological active in the various vehicles.
  • the penetration-enhancing compositions of the present invention contains less than about 10%, preferably less than 3.5%, more preferably less than about 1%, and most preferably less than about 0.5%, of any specific compound, or member of the group of compounds, described by this term.
  • compositions of this disclosure contain a cosmetic agent and/or pharmaceutically-active agent capable of producing or possessing local activity, in a binary vehicle or carrier.
  • vehicle on carrier comprises a polar lipid, such as lecithin or phosphotidylcholine, and two biocompatible organic solvents, one chosen from the group of esters and one chosen from the group of liquid dihydric and polyhydric alcohols, a preservative, water, a thickener and urea, at a pH of between about 5.5 and 7.5 and preferably between 6.0 and 7.0.
  • the compositions of this disclosure may additionally contain other optional components that reduce skin irritation, or enhance their cosmetic appeal or acceptability, e.g, pigments, fragrances, perfumes, and the like.
  • Typical polar lipids employed are lecithin and phosphotidylcholine.
  • the lecithin or phosphatidylcholine is of a high quality, pharmaceutical grade.
  • Appropriate lecithin and phosphatidylcholine maybe obtained as commercially available soya lecithin or soya phosphatidylcholine.
  • soya lecithin is used in the composition of this invention.
  • the biocompatible organic ester solvents may be any non-toxic ester in which the polar lipid, the cosmetic or pharmaceutically active compound and urea are soluble, and which assists as a solubilizing vehicle for carrying cosmetic or pharmaceutically active compounds across the skin of a mammal.
  • the esters are fatty mono esters having a structure, obtainable by replacing the active hydrogen of a fatty acid having 4 to 22 carbon atoms and more typically having 8 to 18 carbon atoms by the alkyl group of a monohydric alcohol, particular example being 12 carbon atoms.
  • the fatty acid can be saturated or unsaturated and more typically is saturated.
  • the monohydric alcohol typically contains 2 to 8 carbon atoms and more typically 2 to 5 carbon atoms, a particular example being 3 carbon atoms.
  • Acceptable esters for this purpose include, but are not limited to isopropyl esters.
  • the ester is isopropyl myristate or isopropyl palmitate, with isopropyl myristate being particularly preferred.
  • the biocompatible organic dihydric and polyhydric alcohol solvents may be any non-toxic di or polyalcohol in which the polar lipid and the active compound are soluble, and which assists as a solubilizing vehicle for carrying active compounds across the skin of a mammal.
  • Acceptable dihydric and polyalcohols for this purpose include, but are not limited to di- and tri-alcohol alkanes.
  • the alcohols contain 3 to 8 carbon atoms and more typically 3 to 5 carbon atoms and are saturated alcohols.
  • the polyalcohol is propylene glycol or glycerol, with propylene glycol being particularly preferred.
  • compositions of the present disclosure typically contain about 2 to 30% by weight and more typically 4 to 10% by weight of the ester and about 0.5 to about 20% by weight, more typically 1 to about 20% weight, and even more typically 1 to about 10% weight of the alcohol. Many of the compositions contain about 2 to about 20% by weight or, 2 to about 10% weight of the alcohol. Compositions according to the present disclosure exhibit reduced skin irritation.
  • the polar lipid is typically dissolved in the organic ester solvent and di or polyalcohol solvent at mass ratios from about 5:1:1 to about 1:5:5.
  • the polar lipid and organic ester solvent and polyalcohol solvent are mixed in equal mass ratios.
  • soya lecithin, isopropyl myristate, and propylene glycol are mixed in equal mass ratios and mixed until the lecithin is evenly distributed. This is referred to as the solvent-polar lipid mixture.
  • a surfactant can be included in the formulation at a concentration of between about 1-20% of the final composition mass.
  • a surfactant is one which is compatible with administration in vivo without elicitation of undesirable side effects.
  • One preferred surfactant is docusate sodium and its more water soluble form, docusate sodium benzoate.
  • ionic or non-ionic surfactants such as polysorbate 80, Tween 80, docusate calcium, tetradecyltrimethylammonium bromide, pentaoxyetylene glycol monododecyl ether, or triethanolamine laureth sulfate. Once the surfactant is thoroughly dispersed in the solvent-polar lipid mixture, the cosmetic or pharmaceutically active compound may be added and dissolved.
  • the dosage of the cosmetic or pharmaceutical agent will, of course, vary depending upon known factors, such as the cosmetic or pharmaceutical agent characteristics of the particular agent; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired.
  • a daily dosage of active ingredient can be expected to be about 0.001 to 1000 milligrams (mg) per kilogram (kg) of body weight, with the more typical dose being 0.1 to about 30 mg/kg.
  • the active agent is typically present in amounts of about 0.001 to about 30%, more typically about 0.001 to about 20%, and even more typically about 0.5 to 12% by weight based upon the total of the delivery system and active agent. For solid active ingredients, this is most easily achieved by heating an aliquot of the surfactant-solvent-polar lipid mixture and adding, on a mass basis, an amount of active compound equal to about 0.01 to 30% of the mass of the surfactant-solvent-polar lipid and mixing until completely dissolved.
  • about 1-20 grams of nifedipine in a powdered form is added to about 100 grams of heated 1:0.5:0.5 soya lecithin:isopropyl myristate:propylene glycol and allowed to dissolve with stirring.
  • Some exemplary active agents include vasodilating agents such as glyceryl trinitrate and nifedipine; antimicrobial or antifungal agents such as ciclopirox, itraconazole, metronidazole, miconazole and allylamines such as, naftifine and terbinafine and salts thereof; inhibitors of cell growth or proliferation, such as 2-deoxy-D-glucose; inhibitors of polyamine transport; inhibitors of polyamine synthesis; antizyme inducers; decalcifying skin agents such as lactic acid; anti-inflammatory agents such as ibuprofen and ketoprofen; topical anaesthetics such as lidocaine; steroidal anti-inflammatory compounds, such as cortisone; peptides, proteins, or hormones, such as platelet factor 4; substance P antagonists such as capsaicin; muscle relaxants such as cyclobenzaprine; anti-inflammatory analgesics such as diclofenac sodium and phosphodieste
  • the active in the case of the active nitroglycerin, is available in the form of a 10% concentration in propylene glycol, which can be added directly to the polar lipid -solvent-surfactant mixture.
  • the amount of a vasodilator for the treatment of peripheral arterial diseases is typically about 0.2 to about 1.8% of the composition.
  • the amount of antimicrobial agent or antifungal agent for the treatment of infectious diseases of the skin and nails, including onychomycosis, athlete's foot, rosacea, and vaginomycosis is typically about 0.5 to about 12% by weight.
  • the amount of an inhibitor of cell growth or proliferation for treatment of actinic keratosis is about 0.001 to about 10% of weight.
  • the amount of an inhibitor of polyamine transport is typically about 0.001 to about 5% by weight.
  • the amount of an inhibitor of polyamine synthesis for the treatment of an automimmune disease, including cutaneous lupus erythrematosus, urticaria, psoriasis, and atopic dermatosis is typically about 0.001 to about 5% by weight.
  • the amount of a decalcifying skin agent, such as lactic acid, for the treatment of dry skin conditions, including xerosis, scleroderma, and ichthyosis is typically about 0.5 to about 10% by weight.
  • two or more different types of active agents can be employed in order to treat more than one condition at the same time.
  • two or more active agents can be used to treat inflammatory, autoimmune, infectious and/or dry skin conditions simultaneously.
  • an amount of urea preferably as a thickened aqueous solution, can be added to the surfactant-solvent-polar lipid mixture.
  • the urea is typically added so that the urea concentration about 1% to about 15% and more typically about 5% and 10% by mass of the final composition mass.
  • the thickener is selected from common National Formulary thickening agents including, but not limited to appropriate polymer weights of polyethylene glycol, polyvinylpyrrolidone, carbomer and methylcellulose.
  • the amount of thickener is typically about 0.05 to about 5% by weight.
  • a 10% aqueous solution of urea containing 0.7% Carbomer 934
  • the pharmaceutically active agent will more readily dissolve if added after addition of the aqueous urea solution, and in other instances before the addition of aqueous urea solution. In any event, this is a choice readily made by those skilled in the art, once aware of the present disclosure, depending on the particular formulation being prepared and the solubility characteristics of the particular cosmetic or pharmaceutically active compound being solubilized.
  • the active agent is a protein
  • the pH is adjusted to typical pH of about 5.5 to about 7.5 and more typically to a 6.0 to 7.0.
  • a base such as aqueous sodium hydroxide and trolamine
  • an acid to reduce the pH would be desirable.
  • an acid such as citric acid or a biological buffer such as sodium carbonate or potassium phosphate.
  • the composition is formulated with a vasodilating agent, such as glyceryl trinitrate.
  • a vasodilating agent such as glyceryl trinitrate.
  • Such formulation is rapidly absorbed through the skin and provides local vasodilation, increases in blood flow, and restoration of normal temperature to an extremity with low blood flow.
  • the composition is formulated with an anti-infective agent. Such formulation is rapidly absorbed through the skin, or somewhat more slowly through the nails to provide local delivery to kill invading microorganisms such as fungi or bacteria.
  • compositions can contain auxiliary agents including those conventionally known and/or used in this art such as, but not limited to, preservatives and fragrances.
  • MQX-GEL a first gel composition
  • a MQX-GEL may be prepared by mixing lecithin organogel (L.O.), as a 1:1:1 (ni/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O. and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
  • L.O. lecithin organogel
  • LID oil a 1:1 [m/m] mixture of L.O. and docusate sodium
  • the solubilized active ingredients may then be added to MQX-GEL.
  • Excipients which may be useful in solubilizing the active ingredient include L.O., propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
  • formulations described above have been prepared, use of the formulations is a simple matter of applying the formulation to affected areas where cutaneous delivery of the pharmaceutically active agent is desired.
  • formulations containing glyceryl trinitrate are rubbed over the affected area such as the fingers of the hands. Treatment is repeated as symptoms reappear or when used as a prophylactic treatment, just before symptoms may appear.
  • normal blood flow in the fingers of the Raynaud's patient has been restored within five minutes of application.
  • an anti-fungal anti-microbial compound is formulated for delivery to toe nails infected with fungus.
  • doctors and patients across the country have confirmed almost complete reduction in fungal infection. This is in contrast to results observed with current commercial topical formulations with this same active ingredient that provide very modest reduction in fungal infection in the same time frame.
  • compositions comprising an antibacterial agent are prepared, for example, by inclusion of bacitracin or another appropriate antibiotic. This allows for penetration of the antibacterial agent to sites of infection induced by puncture wounds.
  • compositions of this invention are provided at a concentration of between about 0.001% to 30% by weight of active compound.
  • compositions comprising more than one active ingredient are within the scope of this disclosure and could be administered to a recipient in need of more than a single active treatment at one localized spot.
  • a composition comprising a vasodilating agent and an antifungal would both provide relief from fungal infection and will facilitate long-term relief by restoring blood flow and the flow of nutrients to the affected area.
  • compositions of this disclosure are applied topically as frequently as required as long as local reactions or toxicity due to the active ingredient do not become a problem.
  • a more rigorously monitored regimen of application may be required when an anti-neoplastic compound is being administered than when a readily metabolized non-toxic compound such as ketoprofen is administered.
  • LID Oil 500 gm LID Oil* 50 gm Lecithin organogel** (L.O.) 100 gm Docusate sodium powder 50 gm Urea 50 gm Thickener 5 gm Distilled water 245 ml
  • LID oil is a 1:1 mixture of lecithin organogel:docusate sodium on a mass basis. **L.O. is a 1:1:1 mixture of lecithin, isopropyl myristate and propylene glycol.1. The LID was added to L.O. and heated.
  • MQX-GEL may just as easily be prepared as follows: 1000 gm L.O. 250 gm Docusate sodium benzoate powder 150 gm Urea 100 gm Thickener 10 gm Distilled water 490 ml
  • the L.O. was heated and the docusate sodium benzoate powder was stirred into the heated L.O. until a smooth solution is prepared.
  • the water was heated and the thickener and urea were dissolved into the water, and the thickened urea solution was then thoroughly mixed with the docusate sodium containing solution of L.O.
  • the result was a consistent, transparent, amber colored gel with a pH of about 6.0.
  • a further method of making MQX-GEL is as follows: 1000 gm L.O. 100 gm LID 300 gm Urea 100 gm Thickener 10 gm Distilled water 490 gm
  • the LID and L.O. were mixed well and a heated solution of water, the thickener and the urea was prepared and added to the LID-L.O. solution.
  • the result was a consistent, transparent, amber colored gel with a pH of about 6.0.
  • MQX-GEL can also be prepared with other ratios of the three constituents of the lecithin organogel.
  • the ratio of lecithin organogel (L.O. #2), is a 1:0.9:0.1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [nm/m] mixture of L.O.#2 and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
  • the solubilized active ingredients may then be added to MQX-GEL.
  • Excipients which may be useful in solubilizing the active ingredient include L.O.#2, propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
  • a formulation is prepared along the lines of Example 6 containing 2% miconazole nitrate, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 2% naftifine hydrochloride, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 5% terbinafine hydrochloride, 45.5% distilled water, 9.75% urea, 0.7% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 NNaOH.
  • a formulation is prepared along the lines of Example 6 containing 2% ciclopirox olamine, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 4% ciclopirox olamine, 46.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0NNaOH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/150,254 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications Abandoned US20060078580A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US11/150,254 US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
EP05811827A EP1796632A4 (fr) 2004-10-08 2005-10-11 Formulations a base d'organogel destinee a des applications therapeutiques
MX2007003995A MX2007003995A (es) 2004-10-08 2005-10-11 Formulaciones de organo-gel para aplicaciones terapeuticas.
NZ551887A NZ551887A (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
SG200906727-3A SG156624A1 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
JP2007535827A JP2008515911A (ja) 2004-10-08 2005-10-11 治療用のオルガノゲル調製物
AU2005294216A AU2005294216C1 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
BRPI0512583A BRPI0512583B8 (pt) 2004-10-08 2005-10-11 composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções
KR1020077003283A KR20070072482A (ko) 2004-10-08 2005-10-11 치료적 응용을 위한 유기겔 제제형
CA002567575A CA2567575C (fr) 2004-10-08 2005-10-11 Formulations a base d'organogel destinee a des applications therapeutiques
PCT/US2005/036064 WO2006042059A1 (fr) 2004-10-08 2005-10-11 Formulations a base d'organogel destinee a des applications therapeutiques
US11/246,296 US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
CN2005800342224A CN101035509B (zh) 2004-10-08 2005-10-11 用于治疗用途的有机凝胶制剂
IL180691A IL180691A (en) 2004-10-08 2007-01-14 Organo-gel formulations for therapeutic applications
US12/856,292 US20100305081A1 (en) 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/960,516 US7740875B2 (en) 2004-10-08 2004-10-08 Organo-gel formulations for therapeutic applications
US11/066,485 US20060078579A1 (en) 2004-10-08 2005-02-28 Organo-gel formulations for therapeutic applications
US11/150,254 US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/066,485 Continuation-In-Part US20060078579A1 (en) 2004-10-08 2005-02-28 Organo-gel formulations for therapeutic applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/246,296 Continuation-In-Part US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications

Publications (1)

Publication Number Publication Date
US20060078580A1 true US20060078580A1 (en) 2006-04-13

Family

ID=36148664

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/150,254 Abandoned US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
US11/246,296 Active 2027-09-17 US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
US12/856,292 Abandoned US20100305081A1 (en) 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/246,296 Active 2027-09-17 US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
US12/856,292 Abandoned US20100305081A1 (en) 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications

Country Status (8)

Country Link
US (3) US20060078580A1 (fr)
EP (1) EP1796632A4 (fr)
JP (1) JP2008515911A (fr)
KR (1) KR20070072482A (fr)
AU (1) AU2005294216C1 (fr)
BR (1) BRPI0512583B8 (fr)
CA (1) CA2567575C (fr)
WO (1) WO2006042059A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078579A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
US20100016446A1 (en) * 2008-07-21 2010-01-21 Sylvia Gonda Stable water-based topical pharmaceutical creams and methods of making and using same
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US7776349B2 (en) 2004-10-08 2010-08-17 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2014202550A3 (fr) * 2013-06-17 2015-04-23 Hestia Investments Composition pour utilisation topique dans la prévention et le traitement d'infections fongiques et bactériennes de la peau et des muqueuses
EP3560485A1 (fr) * 2011-05-03 2019-10-30 Aponia Laboratories, Inc. Compositions transdermiques d'ibuprofène et leurs procédés d'utilisation
US11413323B2 (en) 2018-10-12 2022-08-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11813354B1 (en) * 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
US12128010B2 (en) 2015-09-30 2024-10-29 Novaliq Gmbh Semifluorinated compounds and their compositions
US12150955B2 (en) 2017-04-21 2024-11-26 Dermaliq Therapeutics, Inc. Iodine compositions
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078597A1 (en) * 2002-07-24 2006-04-13 Basf Aktiengesellschaft Ascorbic acid salt suspensions and use thereof as antioxidants
ES2288133B1 (es) * 2006-06-12 2008-09-16 Maria Cristina Fernandez Rodriguez Composicion topica para el tratamiento de la psoriasis.
US8052984B2 (en) 2007-02-05 2011-11-08 Biophile Corporation, Ltd. Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages
EP1958639A1 (fr) * 2007-02-14 2008-08-20 Polichem S.A. Utilisation de chitosanes dans le traitement de maladies inflammatoires des ongles
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
WO2009054992A1 (fr) * 2007-10-25 2009-04-30 Ivrea Pharmaceuticals, Inc. Compositions antimicrobiennes comprenant du docusate
CA2731455A1 (fr) * 2008-07-23 2010-01-28 Gregor Cevc Procede d'administration de formulations antifongiques topiques pour le traitement d'infections fongiques
AU2009313928B2 (en) * 2008-11-14 2015-07-09 Archer Daniels Midland Company Organogel compositions and processes for producing
AU2009339445A1 (en) * 2009-02-05 2011-08-18 Targeted Delivery Technologies Limited Methods of reducing the proliferation and viability of microbial agents
JP5582467B2 (ja) * 2009-04-23 2014-09-03 学校法人日本大学 レシチンおよび尿素を主成分とする逆紐状ミセルから成るオイルゲル
US20100273834A1 (en) * 2009-04-25 2010-10-28 Reza Babapour Treatment of onychomycosis and related compositions including urea
CA2785643A1 (fr) * 2009-12-23 2011-06-30 Nuvo Research Inc. Formule de terbinafine hautement permeable
MX2012010684A (es) 2010-03-17 2012-11-06 Novaliq Gmbh Composicion farmaceutica para el tratamiento de la presion intraocular incrementada.
AU2011252887B2 (en) 2010-05-14 2016-05-12 Archer Daniels Midland Company Food compositions comprising organogels
EP2444063A1 (fr) 2010-10-20 2012-04-25 Novaliq GmbH Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr) 2010-11-11 2012-06-13 Novaliq GmbH Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
CA2834855C (fr) 2011-05-25 2020-12-29 Novaliq Gmbh Composition pharmaceutique a base d'alcanes semifluore
WO2013072929A2 (fr) 2011-09-23 2013-05-23 Indian Institute Of Technology Composition cosmétique à base d'articles nanoparticulaires
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
CN113694048B (zh) 2012-09-12 2023-03-24 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
MX350588B (es) 2012-09-12 2017-09-11 Novaliq Gmbh Composiciones de alcanos semifluorados.
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
KR102164169B1 (ko) 2013-02-13 2020-10-12 고쿠리쓰다이가쿠호진 규슈다이가쿠 겔화제 및 오가노겔
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
WO2016144121A2 (fr) * 2015-03-12 2016-09-15 동아제약 주식회사 Composition pharmaceutique pour traiter des maladies infectieuses fongiques de tissu de kératine
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
PL3356313T3 (pl) 2015-09-30 2020-11-16 Novaliq Gmbh 2-perfluoroheksylooktan do podawania okulistycznego
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
CA3076776A1 (fr) 2017-09-27 2019-04-04 Novaliq Gmbh Compositions ophtalmiques comprenant du latanoprost, destinees a etre utilisees dans le traitement de maladies oculaires
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
EP3829601B1 (fr) 2018-08-01 2024-05-29 Edix-O Sarl Compositions injectables à durée d'action prolongée pour leur utilisation dans le traitement de maladies de l'ongle
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle
JP7292567B2 (ja) 2018-09-27 2023-06-19 ダーマリック セラピューティクス， インコーポレーテッド 局所日焼け止め製剤
CN112839620A (zh) 2018-09-27 2021-05-25 诺瓦利克有限责任公司 脂质屏障修复剂
IL298928A (en) * 2020-06-30 2023-02-01 Dermira Inc RORγt INHIBITORS AND TOPICAL USES THEREOF

Citations (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) * 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4021573A (en) * 1974-04-22 1977-05-03 The Regents Of The University Of California Psoriasis treatment with retinoic acid analogs
US4036970A (en) * 1975-07-28 1977-07-19 Syntex (U.S.A.) Inc. Imidazol-1-yl propane derivatives
US4567161A (en) * 1982-07-09 1986-01-28 A. Natterman & Cie Gmbh Liquid active ingredient concentrates for preparation of microemulsions
US4684661A (en) * 1984-11-22 1987-08-04 Sandoz Ltd. Anti-fungal homopropargylamines, compositions, and method of use therefor
US4751245A (en) * 1986-06-25 1988-06-14 E. R. Squibb & Sons, Inc. Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
US4755534A (en) * 1979-08-22 1988-07-05 Sandoz Ltd. Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4788061A (en) * 1985-07-05 1988-11-29 Shore Ronald N Extended occlusive treatment of skin disorders
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4920112A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4957730A (en) * 1985-12-19 1990-09-18 Hoechst Aktiengesellschaft Antimycotic nail varnish
US5030625A (en) * 1984-11-22 1991-07-09 Sandoz Ltd. Anti-fungal homopropargylamine compounds
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US5181914A (en) * 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5231183A (en) * 1989-10-02 1993-07-27 Banyu Pharmaceutical Co., Ltd. Process for producing enyne derivatives
US5264206A (en) * 1987-06-16 1993-11-23 Hoechst Aktiengesellschaft Nail lacquer with antimycotic activity, and a process for the preparation thereof
US5318960A (en) * 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5385911A (en) * 1990-12-18 1995-01-31 Merrell Dow Pharmaceuticals Inc. Anti-herpes castanospermine esters
US5401742A (en) * 1993-05-11 1995-03-28 Japan, As Represented By Director General Of Agency Of Industrial Science And Technology Polymeric conjugate of methotrexate compound and pyran copolymer and method for the preparation thereof
US5514698A (en) * 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5591774A (en) * 1986-12-23 1997-01-07 Yu; Ruey J. Method of treating wrinkles using malic acid
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US5652256A (en) * 1995-06-06 1997-07-29 Knowles; W. Roy Topical composition for fungal treatment
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5681849A (en) * 1991-05-20 1997-10-28 Novartis Ag Ltd. Pharmaceutical composition for topical applications
US5693676A (en) * 1994-05-27 1997-12-02 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5753256A (en) * 1993-11-06 1998-05-19 Labtec Gesellschaft Fur Biotechnologische Forschung Und Entwicklung Mbh Plaster for the treatment of nail mycoses
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US5814305A (en) * 1991-03-08 1998-09-29 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US5817875A (en) * 1995-09-20 1998-10-06 Karimian; Khashayar Methods for the manufacture of terbinafine
US5840283A (en) * 1995-09-14 1998-11-24 Sorenson Pharmaceutical, Inc. Composition and method for treating diseased nails
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5985906A (en) * 1995-05-12 1999-11-16 Novartis Ag Antifungal composition
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
US6017920A (en) * 1994-05-06 2000-01-25 Toko Yakuhin Kogyo Kabushiki Kaisha Antifungal composition for external use being retentive in stratum corneum
US6042845A (en) * 1994-12-22 2000-03-28 Johnson & Johnson Consumer Products, Inc. Anti fungal treatment of nails
US6143794A (en) * 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US6159977A (en) * 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US6165975A (en) * 1997-06-23 2000-12-26 Queen's University At Kingston Microdose therapy
US6172261B1 (en) * 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
US6287601B1 (en) * 1996-11-19 2001-09-11 Meri Charmyne Russell Topical nitric oxide donor compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
US6538017B2 (en) * 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US20030086881A1 (en) * 2000-03-09 2003-05-08 Aventis Pharma Deutschland Gmbh Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
US6596287B2 (en) * 1997-05-27 2003-07-22 Semibiosys Genetics Inc. Products for topical applications comprising oil bodies
US20030181526A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20030181525A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6632843B1 (en) * 2000-02-01 2003-10-14 Mark Friedman Treatment of bruxism
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20040039030A1 (en) * 1996-09-27 2004-02-26 Hoechst Akeengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US20040058954A1 (en) * 2002-09-23 2004-03-25 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme framshifting
US20040062733A1 (en) * 2002-09-27 2004-04-01 Birnbaum Jay E. Subunguicide, and method for treating onychomycosis
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20040081684A1 (en) * 1996-02-19 2004-04-29 Monash University Topical delivery of antifungal agents
US20040096410A1 (en) * 2002-07-29 2004-05-20 Maley Joseph C. Methods and compositions for treatment of dermal conditions
US20040101538A1 (en) * 2001-03-30 2004-05-27 Catherine Larnier Topical composition
US6743417B2 (en) * 2002-04-22 2004-06-01 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US20040167079A1 (en) * 2003-01-10 2004-08-26 George Tidmarsh Treatment of cancer with 2-deoxyglucose
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20050074414A1 (en) * 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
US20060078577A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060110342A1 (en) * 2004-10-08 2006-05-25 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
US4782059A (en) 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
CH681427A5 (fr) 1987-07-01 1993-03-31 Zambon Spa
FR2646603B1 (fr) 1989-05-03 1991-07-12 Oreal Composition nettoyante
CA2067807C (fr) 1990-02-08 1998-11-03 Miklos Ghyczy Composition phospholipidique aqueuse alcoolique de type gel, son utilisation, et preparations topiques en contenant
JPH0739325B2 (ja) * 1991-06-24 1995-05-01 株式会社島津製作所 住居用防カビ剤
JP4094230B2 (ja) * 1999-02-05 2008-06-04 メディクエスト セラピューティックス インク アンチザイムモジュレーターおよびその使用
SE0000303D0 (sv) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
ATE380542T1 (de) 2000-10-27 2007-12-15 Leo Pharma As Topische zusammensetzung enthaltend mindestens ein vitamin d oder vitamin d analogon und mindestens ein corticosteroid
BR0206905A (pt) * 2001-02-01 2004-07-06 Biogen Inc Métodos para tratar ou prevenir distúrbios da pele empregando-se agentes de ligação de cd2
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
JP4843169B2 (ja) * 2001-02-27 2011-12-21 株式会社Ａｄｅｋａ 殺菌洗浄剤組成物
WO2003047503A2 (fr) 2001-10-22 2003-06-12 University Of Mississippi Administration de medicaments a l'ongle
JP2004083439A (ja) * 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd 爪用抗真菌外用剤

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) * 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US4021573A (en) * 1974-04-22 1977-05-03 The Regents Of The University Of California Psoriasis treatment with retinoic acid analogs
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4036970A (en) * 1975-07-28 1977-07-19 Syntex (U.S.A.) Inc. Imidazol-1-yl propane derivatives
US4755534A (en) * 1979-08-22 1988-07-05 Sandoz Ltd. Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4567161A (en) * 1982-07-09 1986-01-28 A. Natterman & Cie Gmbh Liquid active ingredient concentrates for preparation of microemulsions
US5030625A (en) * 1984-11-22 1991-07-09 Sandoz Ltd. Anti-fungal homopropargylamine compounds
US4684661A (en) * 1984-11-22 1987-08-04 Sandoz Ltd. Anti-fungal homopropargylamines, compositions, and method of use therefor
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4788061A (en) * 1985-07-05 1988-11-29 Shore Ronald N Extended occlusive treatment of skin disorders
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4957730A (en) * 1985-12-19 1990-09-18 Hoechst Aktiengesellschaft Antimycotic nail varnish
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US4751245A (en) * 1986-06-25 1988-06-14 E. R. Squibb & Sons, Inc. Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
US5591774A (en) * 1986-12-23 1997-01-07 Yu; Ruey J. Method of treating wrinkles using malic acid
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US5264206A (en) * 1987-06-16 1993-11-23 Hoechst Aktiengesellschaft Nail lacquer with antimycotic activity, and a process for the preparation thereof
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US4920112A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US5181914A (en) * 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5296612A (en) * 1989-10-02 1994-03-22 Banyu Pharmaceutical Co., Ltd. Process for producing enyne derivatives
US5231183A (en) * 1989-10-02 1993-07-27 Banyu Pharmaceutical Co., Ltd. Process for producing enyne derivatives
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
US5385911A (en) * 1990-12-18 1995-01-31 Merrell Dow Pharmaceuticals Inc. Anti-herpes castanospermine esters
US6143793A (en) * 1991-03-08 2000-11-07 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US5814305A (en) * 1991-03-08 1998-09-29 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6455592B1 (en) * 1991-03-08 2002-09-24 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6121314A (en) * 1991-05-20 2000-09-19 Novartis Ag Pharmaceutical composition
US5681849A (en) * 1991-05-20 1997-10-28 Novartis Ag Ltd. Pharmaceutical composition for topical applications
US5856355A (en) * 1991-05-20 1999-01-05 Novartis Ag Pharmaceutical composition
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) * 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5401742A (en) * 1993-05-11 1995-03-28 Japan, As Represented By Director General Of Agency Of Industrial Science And Technology Polymeric conjugate of methotrexate compound and pyran copolymer and method for the preparation thereof
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5753256A (en) * 1993-11-06 1998-05-19 Labtec Gesellschaft Fur Biotechnologische Forschung Und Entwicklung Mbh Plaster for the treatment of nail mycoses
US5514698A (en) * 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US6017920A (en) * 1994-05-06 2000-01-25 Toko Yakuhin Kogyo Kabushiki Kaisha Antifungal composition for external use being retentive in stratum corneum
US5693676A (en) * 1994-05-27 1997-12-02 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US6042845A (en) * 1994-12-22 2000-03-28 Johnson & Johnson Consumer Products, Inc. Anti fungal treatment of nails
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US6316428B1 (en) * 1995-03-10 2001-11-13 Wilson Trafton Crandall Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5985906A (en) * 1995-05-12 1999-11-16 Novartis Ag Antifungal composition
US5652256A (en) * 1995-06-06 1997-07-29 Knowles; W. Roy Topical composition for fungal treatment
US5889039A (en) * 1995-06-06 1999-03-30 Knowles; W. Roy Topical composition for fungal treatment
US5840283A (en) * 1995-09-14 1998-11-24 Sorenson Pharmaceutical, Inc. Composition and method for treating diseased nails
US5817875A (en) * 1995-09-20 1998-10-06 Karimian; Khashayar Methods for the manufacture of terbinafine
US20040081684A1 (en) * 1996-02-19 2004-04-29 Monash University Topical delivery of antifungal agents
US20040039030A1 (en) * 1996-09-27 2004-02-26 Hoechst Akeengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US6287601B1 (en) * 1996-11-19 2001-09-11 Meri Charmyne Russell Topical nitric oxide donor compositions
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6596287B2 (en) * 1997-05-27 2003-07-22 Semibiosys Genetics Inc. Products for topical applications comprising oil bodies
US6165975A (en) * 1997-06-23 2000-12-26 Queen's University At Kingston Microdose therapy
US6610652B2 (en) * 1997-06-23 2003-08-26 Queen's University At Kingston Microdose therapy
US6423683B1 (en) * 1997-06-23 2002-07-23 Queens University At Kingston Microdose therapy
US6172261B1 (en) * 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US6143794A (en) * 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6159977A (en) * 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6632843B1 (en) * 2000-02-01 2003-10-14 Mark Friedman Treatment of bruxism
US20030086881A1 (en) * 2000-03-09 2003-05-08 Aventis Pharma Deutschland Gmbh Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
US20010049386A1 (en) * 2000-04-12 2001-12-06 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6380236B2 (en) * 2000-04-12 2002-04-30 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
US6538017B2 (en) * 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US20040101538A1 (en) * 2001-03-30 2004-05-27 Catherine Larnier Topical composition
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
US6673842B2 (en) * 2002-03-20 2004-01-06 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20030181525A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20030181526A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6743417B2 (en) * 2002-04-22 2004-06-01 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US20040146470A1 (en) * 2002-04-22 2004-07-29 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040096410A1 (en) * 2002-07-29 2004-05-20 Maley Joseph C. Methods and compositions for treatment of dermal conditions
US20040058954A1 (en) * 2002-09-23 2004-03-25 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme framshifting
US20040062733A1 (en) * 2002-09-27 2004-04-01 Birnbaum Jay E. Subunguicide, and method for treating onychomycosis
US20050074414A1 (en) * 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
US20040167079A1 (en) * 2003-01-10 2004-08-26 George Tidmarsh Treatment of cancer with 2-deoxyglucose
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20060078577A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078579A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060110342A1 (en) * 2004-10-08 2006-05-25 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078577A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7776349B2 (en) 2004-10-08 2010-08-17 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078579A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
US20100016446A1 (en) * 2008-07-21 2010-01-21 Sylvia Gonda Stable water-based topical pharmaceutical creams and methods of making and using same
EP2379070A4 (fr) * 2008-07-21 2013-11-13 Imi Internat Medical Innovations D B A Procris Pharmaceuticals Crèmes pharmaceutiques topiques stables à base d'eau et procédés pour les préparer et les utiliser
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
EP3560485A1 (fr) * 2011-05-03 2019-10-30 Aponia Laboratories, Inc. Compositions transdermiques d'ibuprofène et leurs procédés d'utilisation
WO2014202550A3 (fr) * 2013-06-17 2015-04-23 Hestia Investments Composition pour utilisation topique dans la prévention et le traitement d'infections fongiques et bactériennes de la peau et des muqueuses
US12128010B2 (en) 2015-09-30 2024-10-29 Novaliq Gmbh Semifluorinated compounds and their compositions
US12150955B2 (en) 2017-04-21 2024-11-26 Dermaliq Therapeutics, Inc. Iodine compositions
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US11413323B2 (en) 2018-10-12 2022-08-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12059449B2 (en) 2018-10-12 2024-08-13 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11813354B1 (en) * 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Also Published As

Publication number Publication date
US20060110342A1 (en) 2006-05-25
EP1796632A4 (fr) 2009-03-11
CA2567575C (fr) 2009-01-20
AU2005294216A1 (en) 2006-04-20
AU2005294216B2 (en) 2010-06-24
CA2567575A1 (fr) 2006-04-20
BRPI0512583A (pt) 2008-03-25
EP1796632A1 (fr) 2007-06-20
KR20070072482A (ko) 2007-07-04
BRPI0512583B8 (pt) 2021-05-25
WO2006042059A1 (fr) 2006-04-20
US20100305081A1 (en) 2010-12-02
AU2005294216C1 (en) 2011-02-24
JP2008515911A (ja) 2008-05-15
BRPI0512583B1 (pt) 2018-12-26
US7776349B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
US7776349B2 (en) Organo-gel formulations for therapeutic applications
US7740875B2 (en) Organo-gel formulations for therapeutic applications
RU2429815C2 (ru) Безводная многофазная гелевая система
US10821075B1 (en) Compositions for topical application of a medicaments onto a mammalian body surface
DE3779999T2 (de) Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
US5639740A (en) Topical moisturizing composition and method
US5889039A (en) Topical composition for fungal treatment
US6894078B2 (en) Alcohol based topical anesthetic formulation and method
US20090191138A1 (en) Novel topical formulations for improving the appearance of nails
US20110236503A1 (en) Topical Skincare Composition
WO1998042348A1 (fr) Composition hydratante topique et methode associee
RU2238092C2 (ru) Водная лекарственная композиция для лечения заболеваний кожи
US20240180837A1 (en) Method for Treating Inflammatory Skin Conditions and other Topical Conditions or Disorders
Sharma et al. EMULGEL: A TOPICAL DRUG DELIVERY
AU2012261730A1 (en) Anhydrous multiphase gel system
HK1116666A (en) Anhydrous multiphase gel system

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDIQUEST THERAPEUTICS, INC., WASHINGTON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DECHOW, FREDERICK J.;REEL/FRAME:016468/0210

Effective date: 20050607

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION